ID: ALA3910597

Max Phase: Preclinical

Molecular Formula: C29H28Cl3FN2O4S

Molecular Weight: 625.98

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2Cl)c(C(C)(C)c2c(Cl)cccc2Cl)n1

Standard InChI:  InChI=1S/C29H28Cl3FN2O4S/c1-28(2,26-19(30)7-6-8-20(26)31)27-34-25(29(3,4)37)14-35(27)23-10-9-16(11-21(23)32)17-12-22(33)18(15-36)24(13-17)40(5,38)39/h6-14,36-37H,15H2,1-5H3

Standard InChI Key:  PCAWBEDTJCPNOG-UHFFFAOYSA-N

Associated Targets(Human)

Retinoic acid receptor RXR-alpha/oxysterols receptor LXR-beta 97 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Retinoic acid receptor RXR-alpha/oxysterols receptor LXR-alpha 132 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

LXR-beta 3841 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

LXR-alpha 2891 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 625.98Molecular Weight (Monoisotopic): 624.0819AlogP: 7.09#Rotatable Bonds: 7
Polar Surface Area: 92.42Molecular Species: NEUTRALHBA: 6HBD: 2
#RO5 Violations: 2HBA (Lipinski): 6HBD (Lipinski): 2#RO5 Violations (Lipinski): 2
CX Acidic pKa: 13.64CX Basic pKa: 4.79CX LogP: 6.78CX LogD: 6.78
Aromatic Rings: 4Heavy Atoms: 40QED Weighted: 0.23Np Likeness Score: -0.80

References

1. Kick EK, Busch BB, Martin R, Stevens WC, Bollu V, Xie Y, Boren BC, Nyman MC, Nanao MH, Nguyen L, Plonowski A, Schulman IG, Yan G, Zhang H, Hou X, Valente MN, Narayanan R, Behnia K, Rodrigues AD, Brock B, Smalley J, Cantor GH, Lupisella J, Sleph P, Grimm D, Ostrowski J, Wexler RR, Kirchgessner T, Mohan R..  (2016)  Discovery of Highly Potent Liver X Receptor β Agonists.,  (12): [PMID:27994765] [10.1021/acsmedchemlett.6b00234]

Source